Castle Biosciences, Inc. - SIC # 8071 - MEDICAL LABORATORIES

Ticker Exchange SIC # Website Latest Ticker
CSTL Nasdaq 8071 castlebiosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Castle Biosciences, Inc.

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 19th, 2025 5:00 am
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases - Jun 16th, 2025 2:30 pm
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - Jun 11th, 2025 5:00 am
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - Jun 4th, 2025 5:00 am
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025 - May 29th, 2025 9:56 pm
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes - May 29th, 2025 2:30 pm
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - May 21st, 2025 5:00 am
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result - May 9th, 2025 5:00 am
Castle Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - May 7th, 2025 5:05 am
Castle Biosciences Celebrates Skin Cancer Awareness Month - May 7th, 2025 5:00 am
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - May 6th, 2025 1:07 am
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates - May 5th, 2025 3:15 pm
Castle Biosciences Reports First Quarter 2025 Results - May 5th, 2025 2:06 pm
Castle Biosciences to Acquire Previse - May 5th, 2025 2:05 pm
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer - May 2nd, 2025 2:30 pm
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity - Apr 30th, 2025 3:00 pm
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma - Apr 28th, 2025 5:00 am
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis - Apr 25th, 2025 2:15 pm
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 - Apr 14th, 2025 5:00 am
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships - Apr 8th, 2025 5:00 am